Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/AMGEN R&D AND MARKETING AGREEMENT COVERS THREE DNA COMPOUNDS

Executive Summary

J&J/AMGEN R&D AND MARKETING AGREEMENT COVERS THREE DNA COMPOUNDS; erythropoietin, interleukin-2, and a hepatitis B vaccine. The agreement-in-principle, announced Aug. 19, covers the clinical development, manufacturing and marketing of the three genetically engineered pharmaceutical compounds. In addition, the joint venture agreement "calls for milestone payments to Amgen which are expected to exceed $6 mil. during its current fiscal year ]ending March 31,1986[, and substantial payments in future years," a joint release noted. The two firms added that the arrangement is "subject to negotiation of a definitive agreement." Under the agreement, J&J will have "certain marketing rights to erythropoietin in the U.S.," the release states. Amgen said it has retained some U.S. marketing rights. In addition, J&J and Kirin-Amgen, a 50-50 joint venture to develop and market erythropoietin, said in a separate release on Aug. 20 that they reached an agreement-in-principle providing J&J with worldwide marketing rights outside of China, Japan, and unspecified markets in the U.S. Amgen entered into the $24 mil. joint venture with the Japanese firm, Kirin, in May 1984 covering development and marketing of the drug for kidney dialysis- induced anemia. That earlier agreement had given Kirin exclusive marketing rights for Amgen's erythropoietin in Japan and the right to co-market the drug worldwide except in the U.S. The agreement with Amgen also gives J&J worldwide marketing rights for interleukin-2 as well as exclusive marketing rights to the hepatitis B vaccine in all countries except China, the release notes. Amgen said it expects all three products to reach clinical development by the end of calendar year 1985. "All three products will be marketed and sold by Ortho Pharmaceutical and other J&J companies," the release notes. "Amgen and J&J will share manufacturing and profits from sales." In addition to its ties with Kirin and J&J, Amgen also has product development agreements with Abbott covering DNA hybridization probes; with Upjohn covering bovine growth hormone; and with Texaco covering work in specialty chemicals. For J&J, the agreement with Amgen represents the firm's first public relationship with a biotech company aimed at the development and marketing of pharmaceutical compounds. Also in the biotech area, J&J has an active in-house immunobiology group at Ortho Pharmaceutical, which has developed a number of monoclonal antibody tests marketed by Ortho Diagnostics and is currently looking at therapeutic uses for its monoclonal antibodies. In addition, J&J has agreements with Enzo Biochem covering DNA probes; Cambridge Bioscience for work on a second generation AIDS test; and Scripps Institute.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel